434 related articles for article (PubMed ID: 32333549)
1. The Association Between Type 2 Diabetes Mellitus and Parkinson's Disease.
Cheong JLY; de Pablo-Fernandez E; Foltynie T; Noyce AJ
J Parkinsons Dis; 2020; 10(3):775-789. PubMed ID: 32333549
[TBL] [Abstract][Full Text] [Related]
2. [Parkinson's disease and type 2 diabetes mellitus: interrelation of pathogenetic mechanisms and general therapeutic approaches].
Troshneva AY; Ametov AS
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(11. Vyp. 2):12-18. PubMed ID: 36412150
[TBL] [Abstract][Full Text] [Related]
3. Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways.
Green H; Tsitsi P; Markaki I; Aarsland D; Svenningsson P
CNS Drugs; 2019 Feb; 33(2):143-160. PubMed ID: 30687888
[TBL] [Abstract][Full Text] [Related]
4. Parkinson's disease, insulin resistance and novel agents of neuroprotection.
Aviles-Olmos I; Limousin P; Lees A; Foltynie T
Brain; 2013 Feb; 136(Pt 2):374-84. PubMed ID: 22344583
[TBL] [Abstract][Full Text] [Related]
5. Insulin resistance and Parkinson's disease: A new target for disease modification?
Athauda D; Foltynie T
Prog Neurobiol; 2016; 145-146():98-120. PubMed ID: 27713036
[TBL] [Abstract][Full Text] [Related]
6. Repurposing GLP-1 Receptor Agonists for Parkinson's Disease: Current Evidence and Future Opportunities.
Victorino DB; Nejm M; Guimarães-Marques M; Scorza FA; Scorza CA
Pharmaceut Med; 2021 Jan; 35(1):11-19. PubMed ID: 33409802
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's Disease, Diabetes and Cognitive Impairment.
Ashraghi MR; Pagano G; Polychronis S; Niccolini F; Politis M
Recent Pat Endocr Metab Immune Drug Discov; 2016; 10(1):11-21. PubMed ID: 27396477
[TBL] [Abstract][Full Text] [Related]
8. Insulin-releasing or insulin-sensitizing drugs in Parkinson's disease? Choosing a pathway.
Sánchez-Gómez A; Compta Y; Martí MJ
Parkinsonism Relat Disord; 2021 Dec; 93():109-110. PubMed ID: 34696974
[TBL] [Abstract][Full Text] [Related]
9. Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones.
Cardoso S; Moreira PI
Int Rev Neurobiol; 2020; 155():37-64. PubMed ID: 32854858
[TBL] [Abstract][Full Text] [Related]
10. Convergent Molecular Pathways in Type 2 Diabetes Mellitus and Parkinson's Disease: Insights into Mechanisms and Pathological Consequences.
Xxxx S; Ahmad MH; Rani L; Mondal AC
Mol Neurobiol; 2022 Jul; 59(7):4466-4487. PubMed ID: 35575870
[TBL] [Abstract][Full Text] [Related]
11. Emerging neuroprotective effect of metformin in Parkinson's disease: A molecular crosstalk.
Paudel YN; Angelopoulou E; Piperi C; Shaikh MF; Othman I
Pharmacol Res; 2020 Feb; 152():104593. PubMed ID: 31843673
[TBL] [Abstract][Full Text] [Related]
12. Type 2 Diabetes and Parkinson's Disease: A Focused Review of Current Concepts.
Cullinane PW; de Pablo Fernandez E; König A; Outeiro TF; Jaunmuktane Z; Warner TT
Mov Disord; 2023 Feb; 38(2):162-177. PubMed ID: 36567671
[TBL] [Abstract][Full Text] [Related]
13. Therapies modulating insulin resistance in Parkinson's disease: A cross talk.
Sharma T; Kaur D; Grewal AK; Singh TG
Neurosci Lett; 2021 Apr; 749():135754. PubMed ID: 33610666
[TBL] [Abstract][Full Text] [Related]
14. Type 2 Diabetes (T2DM) and Parkinson's Disease (PD): a Mechanistic Approach.
Sabari SS; Balasubramani K; Iyer M; Sureshbabu HW; Venkatesan D; Gopalakrishnan AV; Narayanaswamy A; Senthil Kumar N; Vellingiri B
Mol Neurobiol; 2023 Aug; 60(8):4547-4573. PubMed ID: 37118323
[TBL] [Abstract][Full Text] [Related]
15. System-based approaches to decode the molecular links in Parkinson's disease and diabetes.
Santiago JA; Potashkin JA
Neurobiol Dis; 2014 Dec; 72 Pt A():84-91. PubMed ID: 24718034
[TBL] [Abstract][Full Text] [Related]
16. Does Parkinson's disease and type-2 diabetes mellitus present common pathophysiological mechanisms and treatments?
Lima MM; Targa AD; Noseda AC; Rodrigues LS; Delattre AM; dos Santos FV; Fortes MH; Maturana MJ; Ferraz AC
CNS Neurol Disord Drug Targets; 2014 Apr; 13(3):418-28. PubMed ID: 24059307
[TBL] [Abstract][Full Text] [Related]
17. Type 2 diabetes mellitus augments Parkinson's disease risk or the other way around: Facts, challenges and future possibilities.
Faizan M; Sarkar A; Singh MP
Ageing Res Rev; 2022 Nov; 81():101727. PubMed ID: 36038113
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
[TBL] [Abstract][Full Text] [Related]
19. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort.
Wahlqvist ML; Lee MS; Hsu CC; Chuang SY; Lee JT; Tsai HN
Parkinsonism Relat Disord; 2012 Jul; 18(6):753-8. PubMed ID: 22498320
[TBL] [Abstract][Full Text] [Related]
20. DPP-4 inhibitors and type 2 diabetes mellitus in Parkinson's disease: a mutual relationship.
Alrouji M; Al-Kuraishy HM; Al-Buhadily AK; Al-Gareeb AI; Elekhnawy E; Batiha GE
Pharmacol Rep; 2023 Aug; 75(4):923-936. PubMed ID: 37269487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
